Wednesday, 16 May 2012

Food And Drug Administration-Achillion Pharmaceuticals-Hepatitis C-Fast Track-Aim

Achillion's hepatitis C drug gets FDA fast track

(Reuters) - The U.S. Food And Drug Administration granted a fast track designation to Achillion Pharmaceuticals Inc's experimental hepatitis C drug ACH-3102, currently in an early-stage trial. The fast-track status is designed to expedite the regulatory review of drugs that aim to treat serious diseases and fill unmet medical needs. The New Haven, Connecticut-based company got a fast track designation in January for another of its experimental hepatitis C (HCV) drug ACH-1625, which was in a mid-stage trial. ... read more..

No comments:

Post a Comment